Alamar Biosciences Q3'26 earnings preview: EPS estimate is expected
Alamar Biosciences is scheduled to report Q3'26 results November 3 after the market closes. Revenue and EPS estimates were provided.
Related stories
Oracle Announces $10 Million Stock and $10 Billion Bond Deals
Oracle shares fell after the company announced stock and bond deals.
M impact | EQUITY | Nov 02, 2026, 01:47 PM UTC
Fox Shares Rise After Q1 Results Top Estimates
Fox shares rise after first-quarter results top estimates, supported by advertising.
M impact | EQUITY | Nov 02, 2026, 01:45 PM UTC
AAR Proposes $955 Million and $960 Million Senior Note Offerings
AAR proposed $955 million of senior notes due 2031 and $960 million of senior notes due 2034.
M impact | EQUITY | Nov 02, 2026, 01:45 PM UTC
Teva shares fall after rare brain disorder drug trial halted
US-listed shares of Israel-based Teva fell after a trial of a drug for a rare brain disorder was halted.
M impact | EQUITY | Nov 02, 2026, 01:45 PM UTC
Fox Q1 results beat on advertising strength
Fox shares rose after the company reported Q1 results that beat expectations, citing advertising strength.
M impact | EQUITY | Nov 02, 2026, 01:45 PM UTC
Oracle-Aktien geben nach Ankündigung von Aktien- und Anleihegeschäften nach
Oracle-Aktien fallen nach Bekanntgabe von Aktiengeschäften im Wert von 10 Milliarden US-Dollar und Anleihegeschäften im Wert von 10 Milliarden US-Dollar.
L impact | EQUITY | Nov 02, 2026, 01:44 PM UTC